United Therapeutics (NASDAQ:UTHR) CEO Sells $4,863,715.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $511.97, for a total value of $4,863,715.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $166,105,082.71. The trade was a 2.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Trading Up 1.1%

NASDAQ UTHR traded up $5.58 during trading hours on Tuesday, hitting $518.46. 875,723 shares of the company’s stock were exchanged, compared to its average volume of 492,121. The firm has a market cap of $22.24 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 1.74 and a beta of 0.59. The stock has a 50-day simple moving average of $532.35 and a 200 day simple moving average of $538.04. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company’s revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.41 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on UTHR. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Finally, Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter worth approximately $26,000. Toth Financial Advisory Corp boosted its position in shares of United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares during the last quarter. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. Fiduciary Financial Advisors bought a new stake in United Therapeutics during the second quarter worth $30,000. Finally, WealthCollab LLC grew its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.